"Drug manufacturers are seek­ing to part­ner with rep­utable sup­pli­ers"

Devashish Ohri, Ex­ec­u­tive Vice President, Asia /Mid­dle East, Africa, Avan­tor

BioSpectrum (Asia) - - Front Page -

Avan­tor, the global player in ul­tra-high-pu­rity ma­te­ri­als for the life sciences and ad­vanced tech­nol­ogy mar­kets, com­pleted its ac­qui­si­tion of VWR in Novem­ber 2017. VWR is the lead­ing global in­de­pen­dent provider of prod­ucts, sup­ply chain and ser­vice so­lu­tions to lab­o­ra­tory and pro­duc­tion cus­tomers. The ac­qui­si­tion re­flects an en­ter­prise value of ap­prox­i­mately $6.5 bil­lion. Avan­tor and VWR are now joined to­gether as one com­pany op­er­at­ing un­der the Avan­tor name. With op­er­a­tions in more than 30 coun­tries and a di­verse port­fo­lio that in­cludes more than four mil­lion prod­ucts, its com­bined reach and di­rect chan­nel ac­cess, cus­tom­ized lo­gis­tics and prod­uct re­quire­ments, and strong lo­cal pres­ence in both de­vel­oped and emerg­ing mar­kets will al­low the com­pany to ful­fill its shared vi­sion to be a trusted global part­ner to its cus­tomers and sup­pli­ers in the life sciences and ad­vanced tech­nol­ogy in­dus­tries. In an in­ter­ac­tion with BioSpec­trum Devashish Ohri, Ex­ec­u­tive Vice President, Asia /Mid­dle East, Africa, Avan­tor shared his views on trends, op­por­tu­ni­ties and chal­lenges be­fore the com­pany. Ex­cerpts of the

in­ter­view.

How have the re­cent M&As’ done by Avan­tor helped the growth of the com­pany?

Avan­tor made three sig­nif­i­cant ac­qui­si­tions in the past year to help strengthen the com­pany’s abil­ity to sup­ply in­no­va­tive ma­te­ri­als and ser­vices to cus­tomers in the global life sciences and ad­vanced tech­nol­ogy in­dus­tries. The merger with NuSil Tech­nol­ogy, LLC in Oc­to­ber 2016 en­hances Avan­tor’s abil­ity to be the global leader in ul­tra-high-pu­rity ma­te­ri­als for the life sciences and ad­vanced tech­nol­ogy mar­kets. The ac­qui­si­tion of Pu­ri­tan Prod­ucts, Inc. in April 2017 adds more cGMP man­u­fac­tur­ing ca­pac­ity and en­ables Avan­tor to sup­ply a broader port­fo­lio of high-pu­rity prod­ucts for the bio­pharma, re­search and elec­tronic ma­te­ri­als in­dus­tries. The suc­cess­ful com­ple­tion of its ac­qui­si­tion of VWR be­gins an ex­cit­ing new era for Avan­tor. With en­hanced scale and fa­vor­able long-term in­dus­try dy­nam­ics, we are well po­si­tioned to ac­cel­er­ate growth, ben­e­fit­ing from deeper ac­cess to the high-growth bio­pharma, in­dus­trial, and ap­plied re­search sec­tors.

How is the com­pany look­ing at ‘Make in In­dia Pro­gramme’ de­signed by the govern­ment?

Flag­ship pro­grammes such as ‘Make in In­dia’ point to a vi­sion and roadmap for the In­dian econ­omy to move ahead. These fo­cused ac­tion plans have con­trib­uted pos­i­tively to im­prov­ing the cli­mate for in­vest­ment in the coun­try and we are hopeful this will be an on­go­ing theme in the coun­try. Avan­tor’s in­vest­ments in In­dia have been sup­port­ive of the ‘Make in In­dia’ vi­sion. There are two state of the art ISO/cGMP cer­ti­fied plants man­u­fac­tur­ing phar­ma­ceu­ti­cal ex­cip­i­ents and di­ag­nos­tics kits for cus­tomers in In­dia and for the wider Asia and Mid­dle East re­gion. These plants have re­ceived recog­ni­tion from the govern­ment of In­dia for up­hold­ing the high­est qual­ity and safety stan­dards.

What chal­lenges do you see in the up­com­ing years?

In­dia is the largest sup­plier of generic drugs by vol­ume to the global mar­ket­place. These in­clude a broad range of small-mol­e­cule drugs, over-the-counter prod­ucts, on­col­ogy drugs and more. There is also an in­creas­ing trend for the de­vel­op­ment of large-mol­e­cule drugs, and es­pe­cially gener­ics as more in­no­va­tive drug prod­ucts come off patent.

At the same time, the drug in­dus­try in In­dia is deal­ing with more reg­u­la­tory over­sight, with ma­jor reg­u­la­tory agen­cies, such as the US Food and Drug Ad­min­is­tra­tion (USFDA) and UK Medicines and Health­care prod­ucts Reg­u­la­tory Agency (MHRA) push­ing for stricter norms for pharma com­pa­nies, not only for man­u­fac­tur­ing prac­tices, but also their sup­ply chains and the sources of their in­gre­di­ents or com­po­nents. Ul­ti­mately, this will help the in­dus­try in In­dia in gen­eral, as more and more global manufacturers like Avan­tor look to their In­dian fa­cil­i­ties as key el­e­ments in the global sup­ply chain. Manufacturers of both small- and large-mol­e­cule drugs are seek­ing to part­ner with more rep­utable sup­pli­ers, rather than sim­ply look­ing solely at price; this in turn

Devashish Ohri, Ex­ec­u­tive Vice President, Asia /Mid­dle East, Africa, Avan­tor

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.